Tumors with POLE/POLD1 Mutations Research

Cohort of Tumors With POLE/D1 Mutation

Recruiting Observational Study
Tumors POLE Exonuclease Domain Mutation POLD1 Gene Mutation
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
Federation Francophone de Cancerologie Digestive · Other
Who this trial is looking for

This trial is looking for adult patients whose tumors have specific genetic mutations in the POLE or POLD1 genes. Participants will help researchers understand the characteristics of these tumors.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am at least 18 years old
  • I have a tumor with a POLE exonuclease domain mutation
  • I have a tumor with a POLD1 exonuclease domain mutation
  • My tumor's mutation was diagnosed within the last year

You may not be able to join if

  • I do not have a POLE or POLD1 mutation in my tumor
  • My tumor mutation was found only in research studies
  • I do not want my data registered in this study

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation identified by molecular biology platforms for all stages and primary sites combined

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14) classified as pathogenic by the project working group, including: the 4 hotspots of mutations described (codons 286 (P286R/H/L), 411 (V411L), 459 (S459F), 424 (L424/V/I), (2). * Any tumor presenti…
Contacts

ROSINE GUIMBAUD, PhD.MD

+33 (0)5 61 32 21 42

guimbaud.r@chu-toulouse.fr

CONTACT